Keyphrases
Prostate Cancer
93%
Statins
54%
Radical Prostatectomy
39%
Atorvastatin
39%
Androgen Deprivation Therapy
35%
Prostate Cancer Progression
33%
Statin Use
33%
Aldosterone
33%
Prostate Cancer Risk
29%
Adverse Effects
23%
Aldosterone Synthesis
23%
CYP11B2
22%
Disease-specific Mortality
22%
Sexual Behavior
21%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
21%
High Risk
21%
Large Intestine
20%
Lipids
19%
Lipid Metabolism
19%
Aldosterone Synthase
18%
Randomized Clinical Trial
18%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
18%
Erectile Dysfunction Treatment
16%
Transdermal Estradiol
16%
Common pitfalls
16%
Breast Cancer
16%
Bone Tumor
16%
Fadrozole
16%
Enzalutamide Resistance
16%
Rat Colon
16%
MiR-26a
16%
Cholesterol Levels
16%
Enhancement Effect
16%
Endopelvic Fascia
16%
Postoperative Incontinence
16%
Polygenic Risk Score
16%
Meta-analysis
16%
National Cohort Study
16%
Non-associated
16%
Cardiovascular Disease
16%
Tumor Targeting
16%
Targeting Mechanism
16%
Cancer-specific
16%
Tumor Immune Environment
16%
Randomized Double-blind
16%
Pharmacoepidemiology
16%
Systematic Meta-analysis
16%
Finnish Men
16%
Phase III Clinical Trial
16%
Testing Effect
16%
Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
100%
Statin (Protein)
49%
Atorvastatin
41%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
36%
Androgen
35%
Biological Marker
23%
Placebo
20%
Cohort Study
19%
Castration Resistant Prostate Cancer
18%
Cancer Mortality
17%
Bone Tumor
16%
Fadrozole
16%
Bone Cancer
16%
Aldosterone Synthase
16%
Replacement Therapy
16%
Diethylstilbestrol
16%
Enzalutamide
16%
Cancer Growth
16%
Erectile Dysfunction
16%
Cancer Incidence
16%
Transdermal
16%
Clinical Study
16%
Breast Cancer
16%
Aldosterone
16%
Cardiovascular Disease
16%
Thymidine Kinase 1
16%
Diseases
16%
Overall Survival
11%
Prostate Specific Antigen
11%
Lipidome
10%
Dextran Sulfate
9%
Hypocholesterolemic Agent
9%
Neoplasm
8%
Malignant Neoplasm
7%
Enteritis
7%
Androgen Receptor
5%
Antidiabetic Agent
5%
Lactone
5%
Medicine and Dentistry
Prostate Cancer
74%
Cancer Growth
33%
Aldosterone
33%
Aldosterone Synthase
23%
Colon
19%
Clinical Study
19%
Neoplasm
19%
Lipid Metabolism
19%
Large Intestine
19%
Randomized Clinical Trial
18%
Androgen Deprivation Therapy
16%
Fadrozole
16%
Prostatectomy
16%
Fascia
16%
Meta-Analysis
16%
Atorvastatin
16%
Systematic Review
16%
Incontinence
16%
Immunity
16%
Thymidine Kinase 1
16%
Adverse Effect
16%
Statin
11%
Overall Survival
11%
Dextran Sulfate
9%
Placebo
9%
Enteritis
7%
Surgical Technique
7%
Urine Incontinence
7%
Urinary System
7%
Enuresis
7%
Single Nucleotide Polymorphism
6%
Meta-Regression
6%
Western Blot
6%
Androgen Receptor
6%
Hazard Ratio
5%
Prostate Specific Antigen
5%
